Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
With growth stalling at some of the industry's biggest biotechs is it time to take a leaf out of big pharma's M&A playbook?